Selank for anxiety: what the actual research says
Quick answer
Selank is a synthetic heptapeptide developed in Russia and studied primarily for generalized anxiety and asthenic conditions in small, non-replicated trials. The creator is using it subcutaneously for self-reported workplace stress and general overstimulation, which does not match the populations studied in available literature. No regulatory body in Australia, the US, or the EU has approved selank for any clinical indication, and its long-term safety profile in humans is not established.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @glpn3e1 actually say?
Two hours after injecting selank, @glpn3e1 reports feeling "totally zen" at work. Over the previous week, they say they felt "way calmer, way less anxious." They work a standard corporate job in Sydney and frame the peptide as helping with general overwhelm rather than a clinical anxiety disorder. They also direct followers to an Instagram "peptide cheat sheet" that covers dosing and sourcing.
To be clear about what this is: a single person, one week in, reporting subjective mood changes after starting a compound that has no approved use in Australia or most Western countries. That is not nothing, but it is also nowhere near evidence. The claim is experiential, not medical. The concerning part is the casual referral to dosing and sourcing guidance, which we will get to.
Does the science back this up?
There is actual research on selank, which puts it ahead of many peptides on TikTok. The evidence base is small, dated, and almost entirely from Russian institutions, which matters for how you interpret it.
Selank is a synthetic analogue of the human tetrapeptide tuftsin. Russian research from the 1990s and 2000s, largely conducted at the Institute of Molecular Genetics in Moscow, reported anxiolytic effects in animal models and small human trials. A study by Semenova et al. (2010, Bulletin of Experimental Biology and Medicine) found reduced anxiety and improved cognitive performance in patients with anxiety-asthenic disorders treated with intranasal selank. A separate review by Zozulya et al. (2006, CNS Drug Reviews) described selank as modulating the GABAergic system and influencing serotonin metabolism, which would be plausible mechanisms for an anxiolytic effect.
However, these studies were small, not independently replicated in Western peer-reviewed trials, and conducted in clinical populations with diagnosed disorders, not healthy people managing workplace stress. The gap between "worked in a Russian clinical trial on anxious patients in 2006" and "pin it yourself and feel zen at your desk" is significant.
What did they get wrong (or right)?
Credit where it is due: selank is one of the more studied peptides in the anxiety space, and the mechanism of action is at least biologically coherent. Describing it as calming rather than claiming it treats a disease is a relatively responsible framing. They did not say it cures anxiety disorder, even though the hashtag "anxietydisorder" does some heavy lifting there.
What they got wrong, or at least glossed over, is substantial. First, one week of subjective experience is not a signal. Placebo effects in anxiety studies are robust and well-documented. A 2010 meta-analysis by Rief et al. (Journal of Affective Disorders) found placebo response rates in anxiety trials averaging around 30 to 40 percent. Second, selank is unregulated in Australia. The Therapeutic Goods Administration has not approved it. Sourcing it through unregulated channels, which the Instagram cheat sheet apparently facilitates, raises serious purity and contamination concerns. Third, directing a 5,300-person audience to a dosing guide for an unscheduled, unverified compound is where this crosses from personal anecdote into something more problematic.
What should you actually know?
Selank has a more credible preclinical and early clinical foundation than most peptides being discussed on social media right now. That bar is low, but it is real. The plausible mechanism involves GABA modulation and possible influence on BDNF expression, the latter supported by Kasian et al. (2012, Neurochemical Journal).
What the research does not support is self-administration based on a one-week TikTok testimonial. The studies that do exist used controlled doses in supervised clinical settings, not subcutaneous self-injection based on crowd-sourced cheat sheets. There are no long-term safety studies in humans. Peptide purity from gray-market suppliers is genuinely inconsistent, and injecting a contaminated compound carries infection and immune reaction risks that have nothing to do with the peptide itself.
If you are managing anxiety significant enough that you are seeking out research chemicals, that is worth a proper clinical conversation. There are evidence-based pharmacological and behavioral options with actual safety profiles. Selank is not there yet, scientifically speaking.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Selank for anxiety: what the actual research says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Functional Connectomic Approach to Studying Selank and Semax Effects
Small Russian fMRI study (52 healthy volunteers) of brain connectivity after Semax or Selank; mechanistic and exploratory, not a clinical efficacy trial.
PubMed
Effects of Semax on the Default Mode Network of the Brain
Small human fMRI study (24 adults) of intranasal Semax on brain networks; an imaging-marker study with no clinical outcomes, not replicated outside the originating group.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Selank for anxiety: what the actual research says is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
Selank is a synthetic heptapeptide developed in Russia and studied primarily for generalized anxiety and asthenic conditions in small, non-replicated trials.
FormBlends verdict
Selank is a synthetic heptapeptide developed in Russia and studied primarily for generalized anxiety and asthenic conditions in small, non-replicated trials. The creator is using it subcutaneously for self-reported workplace stress and general overstimulation, which does not match the populations studied in available literature. No regulatory body in Australia, the US, or the EU has approved selank for any clinical indication, and its long-term safety profile in humans is not established.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Selank is a synthetic heptapeptide developed in Russia and studied primarily for generalized anxiety and asthenic conditions in small, non-replicated trials. The creator is using it subcutaneously for self-reported workplace stress and general overstimulation, which does not match the populations studied in available literature. No regulatory body in Australia, the US, or the EU has approved selank for any clinical indication, and its long-term safety profile in humans is not established.
- Selank has more published preclinical and early clinical research than most peptides on social media, but that research comes almost entirely from Russian institutions and has not been independently replicated in Western peer-reviewed trials.
- The primary studies supporting selank's anxiolytic effects used controlled doses in supervised clinical populations with diagnosed anxiety disorders, not healthy adults managing workplace stress (Semenova et al., 2010).
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Selank has more published preclinical and early clinical research than most peptides on social media, but that research comes almost entirely from Russian institutions and has not been independently replicated in Western peer-reviewed trials.
- The primary studies supporting selank's anxiolytic effects used controlled doses in supervised clinical populations with diagnosed anxiety disorders, not healthy adults managing workplace stress (Semenova et al., 2010).
- Placebo response rates in anxiety trials average 30 to 40 percent, meaning one week of subjective calm after starting a new compound is not reliable evidence of pharmacological effect (Rief et al., 2009, Journal of Affective Disorders).
- Selank is not approved by the Therapeutic Goods Administration in Australia or by the FDA in the United States, meaning any circulating supply comes from unregulated gray-market manufacturers with no guaranteed purity standards.
- Selank's proposed mechanisms, including GABA modulation and possible BDNF upregulation, are biologically plausible based on animal studies (Kasian et al., 2012, Neurochemical Journal), but plausible mechanism is not the same as proven human efficacy.
- Publicly directing an audience to self-dosing and sourcing guides for unregulated injectable compounds raises both regulatory and safety concerns that go beyond the peptide's own risk profile.
- If anxiety is significant enough to consider research peptides, that is a signal to pursue a clinical evaluation, where evidence-based treatments with established safety records are available.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
GLPNEEL · TikTok creator
5.3K views on this video
Selank has really helped calm me down no longer feel jittery or overstimulated as much #anxietyrelief #anxietydisorder #biohacking #calm
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by GLPNEEL, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.